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The Impact of Superior Mediastinal Lymph Node
Metastases on Prognosis in Non-small Cell Lung Cancer
Located in the Right Middle Lobe
Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon, MD, PhD,*
Hirofumi Uehara, MD, PhD,* Yuichi Ishikawa, MD, PhD,† and Ken Nakagawa, MD*
Background:We aimed to assess hilar and mediastinal lymph node
involvement and its impact on prognosis in patients with right
middle lobe lung cancer.
Methods: The records of 170 patients undergoing surgery for right
middle lobe non-small cell lung cancer from 1980 to December
2007 were retrospectively examined. There were 45 patients found
to have hilar or mediastinal lymph nodes metastases. This subgroup
included 31 N2 patients and 14 N1 patients, and included 23 women
and 22 men, whose ages ranged from 32 to 83 years (median  61
years). The status of mediastinal, hilar, and interlobar lymph nodes
was assessed according to the seventh edition of the TNM classifi-
cation for lung cancer. Patient records were examined for age,
gender, preoperative nodal status, surgical procedure, metastatic
status of lymph nodes (distribution and numbers), tumor size, and
histologic features (cell type and differentiation degree). Survival
duration was defined as the interval between surgery and death from
the tumor or the most recent follow-up.
Results: For N1 cases (n  14), the most frequent metastatic site
was #12m (lymph nodes adjacent to the middle lobe bronchus),
which occurred in 11 cases; there was one case with metastases in
#11s (lymph nodes between the upper lobe bronchus and bronchus
intermedius), and no case with #11i metastases (lymph nodes be-
tween the right middle and lower lobe bronchi). The most frequent
metastatic mediastinal zone was the subcarinal zone (25/31), and the
superior mediastinal zone also had a high incidence of metastases
(22/31). Sixteen cases had metastases to both the superior and
subcarinal zones, and six cases had metastasis to superior medias-
tinal zone without subcarinal zone metastasis. When #11s or #11i
was involved, eight of nine or five of five, respectively, were N2
cases. Univariate analyses revealed that tumor diameter, cN, status
of lymph node metastases, and operative procedure (pneumonec-
tomy) were significant prognostic factors in N2 cases. Regarding
status of lymph node metastases, superior mediastinal zone metas-
tases, both superior and inferior (subcarinal) zone metastases, and
#11i were significant prognostic factors. Because #11i metastases
and superior mediastinal lymph nodes metastases were highly corre-
lated with each other (p  0.02), two separate models were used in
multivariate analyses. Superior mediastinal metastases (p  0.03) and
#11i metastases (p 0.015) were revealed to be significant independent
prognostic factors, whereas multiple-zone metastases only tended to-
ward significance as an adverse prognostic factor (p  0.054).
Conclusions: Superior mediastinal lymph node metastases and #11i
metastases were significant adverse prognostic factors in patients with
middle lobe lung cancer, and they were associated with each other.
Key Words: Middle lobe cancer, Superior mediastinal lymph node
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The right middle lobe is the smallest lobe in the lung, andlung cancer originating there is much less common than
in the other lobes, occurring in 3.8 to 6.7% of all lung
cancers.1–4 The fact that it is less common may be a reason
that there are a few reports on the prognostic factors of
middle lobe lung cancer.
Lymph drainage from the middle lobe extends to both
superior and inferior mediastinal lymph nodes, and previous
reports have demonstrated a high incidence of metastases to
both the superior and inferior mediastinal zones.1–6 Never-
theless, there are few articles on the relationships between
status of hilar and mediastinal lymph node metastases and
patient prognoses.
In this retrospective study, we aimed to clarify prog-
nostic factors in patients with middle lobe lung cancer who
underwent surgery. Furthermore, we wanted to determine the
association between the status of lymph node metastases and
postoperative prognosis.
PATIENTS AND METHODS
This was a retrospective study. Because individual
patients were not identified, our institutional review board
waived the requirement for obtaining patient consent and
approved this study. Between 1980 and December 2007, 170
patients underwent surgical resection at the Cancer Institute
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Hospital for primary lung cancer originating in the right
middle lobe. Among these patients, 45 were diagnosed with
N1 or N2 disease after lung resection and hilar and medias-
tinal node dissections (Figure 1). The extent of lymph node
dissection was not affected by a suspicion of N1 disease. We
have routinely performed nearly the same dissection (ND2a).
All the 45 study patients were confirmed for their
prognoses. The primary surgical procedure for lymph node
dissection, such as hilar and mediastinal nodal dissection, was
established in Japan in the late 1970s. In our institute, the
extent of lymph node dissection conducted recently is nearly
the same as that during the 1980s. Some cases had sampling
due to disorders such as cardiac or pulmonary, and these
cases were excluded from this study. The resected lymph
nodes were separated according to the map7 in the operating
room by the surgeons. Station 10 nodes dissected in middle
lobe cancer were adjacent to the inferior parts of the main
bronchus, and these nodes were included in the subcarinal
zone according to the new TNM. 7 The other station 10 nodes,
which were adjacent to the upper parts of the main bronchus,
were not routinely dissected, and this area is difficult to
dissect without an upper lobectomy.
This subgroup included 31 N2 patients and 14 N1
patients, and included 23 women and 22 men, whose ages
ranged from 32 to 83 years (median 61 years, Table 1). For
all patients, preoperative staging was performed using chest
computed tomography (CT), abdominal CT or ultrasonogra-
phy, brain CT or magnetic resonance imaging, and bone
scans. Clinical mediastinal and hilar lymph node status was
assessed as positive if the chest CT showed that the short axis
of a node was more than 1.0 cm. CT scans have been used for
evaluating lung cancer staging in our institute since 1980. Of
course, CT imaging quality is different when comparing that
in the 1980s with that in the 2000s. Nevertheless, this study
focused on pathological N status of middle lobe lung cancer,
and the quality of pathological examinations was nearly the
same during the study period. We excluded those patients
who had induction therapy because it seemed to be difficult to
evaluate their pathological node status.
Bulky N2 (shortest mediastinal lymph node diameter
2 cm) patients have not been candidates for surgery in our
institute. Although mediastinoscopy, 18F-fluorodeoxyglu-
cose positron emission tomography, or endobronchial ultra-
sound with transbronchial needle aspiration was applied to
some patients in this series, they were not used for preoper-
ative staging. Follow-up periods ranged from 2 to 302 months
(median follow-up for living patients was 86 months).
The status of mediastinal, hilar, or interlobar nodes was
assessed according to the seventh edition of the TNM classifi-
cation for lung cancer.7 Mediastinal nodes were classified into
the following three zones: superior, subcarinal, and inferior. N1
nodes were classified into two zones as hilar or interlobar, and
peripheral. The interlobar zone was divided into three subgroups
as follows: #12m, lymph nodes adjacent to the middle lobe
bronchus; #11s, lymph nodes between the upper lobe bronchus
and bronchus intermedius; and #11i, lymph nodes between the
right middle and lower lobe bronchi. When a case had medias-
tinal nodal involvement of two or more zones, it was classified
with multiple-zone metastases.
Patient characteristics are summarized in Table 1. Pa-
tient records were examined for age, gender, preoperative
nodal status, surgical procedure, metastatic status of lymph
nodes (distribution and numbers), tumor size, and histologic
features (cell type and degree of differentiation).
Statistical Analysis
Survival duration was defined as the interval between
surgery and death from the tumor, or the most recent follow-
up. Survival rates were calculated using the Kaplan-Meier
method. Univariate analyses were performed using the log-
rank test, 2 test, and logistic regression. Multivariate analy-
ses were performed for variables with p values less than 0.1
by univariate analysis, using the logistic regression test in
StatView J 5.0 (SAS Institute Inc., Cary, NC). A p value less
than 0.05 was considered significant.
RESULTS
Status of Lymph Node Metastases
In N1 cases (n  14), the most frequent metastatic site
was #12m, occurring in 11 cases, and there was one case with
metastases in #11s and 0 cases with #11i metastases (Figure 2).
FIGURE 1. Study group subdivisions. Between 1980 and De-
cember 2007, 170 patients underwent surgical resections for
right middle lobe lung cancer at the Cancer Institute Hospital.
There were 14 N1 cases and 31 N2 cases evaluated.
TABLE 1. Patient Characteristics
Age (yr) 32–83, median: 61
Gender (male/female) 22/23
c-N
N0/N1/N2 23/14/8
c-T
T1/T2/T3/T4 17/24/3/1
p-N
N1/N2 14/31
Histologic type
Adenocarcinoma/others 35/10
Well-differentiated/others 10/35
Surgical procedure
Lobectomy/bilobectomy/pneumonectomy 21/14/10
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The most frequent metastatic mediastinal zone was the
subcarinal zone (25/31 N2 cases). The superior zone also had
a high incidence of metastases (22/31 cases). There were 16
cases with metastases in both the superior and subcarinal
zones; nine cases were metastasized to the subcarinal zone
without the superior mediastinal zone metastasis, and six
cases were metastasized to superior the mediastinal zone
without the subcarinal zone metastasis (Figure 3). When #11s
was involved, eight of nine cases were N2, and when #11i
was involved, all five cases were N2 (Figures 4 and 5).
Survival Rates for Patients with Nodal
Involvement
The postoperative 5-year survival rate for patients with
N1 was 62% and with N2 was 20% (p  0.02). The postop-
erative 5-year survival rate was 83% for 125 N0 patients. The
prognoses for N0 patients with right middle lobe cancers
were not different from those of N0 patients with other
involved lobes.
Prognostic Factors for N2 in the Right Middle
Lobe
Univariate analyses using the variables listed in Table 2
showed that diameter, cN1–2/cN0, status of lymph node
metastases, and operative procedure (pneumonectomy) were
significant prognostic factors. Nevertheless, there was no
difference in prognoses between lobectomy and bilobectomy.
Regarding specific prognostic lymph node metastases, supe-
rior mediastinal zone metastases, both superior and subcari-
nal and interlobar #11i metastases were significant prognostic
factors. Inferior mediastinal zone metastases, and #12m and
FIGURE 2. Distribution of metastatic nodes in N1 cases.
FIGURE 3. Distribution of metastatic nodes in N2 cases.
FIGURE 4. Association of #11s metastases with mediastinal
zone metastases.
FIGURE 5. Association of #11i metastases with mediastinal
zone metastases.
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#11s metastases were not significant. There was no difference
in prognoses between the patients before 1995 and patients
from 1996 and after (5-year survivals of 13.3% and 28.4%;
p  0.28).
Significant variables by univariate analyses were ana-
lyzed by multivariate analyses (Table 3, models 1 and 2).
Because #11i metastases and superior mediastinal lymph
nodes metastases were highly correlated with each other (p
0.02), two separate models were used for multivariate analyses.
In model 1, superior mediastinal metastases were revealed to be
a significant independent prognostic factor (p 0.03). In model
2, #11i metastases were revealed to be a significant indepen-
dent prognostic factor (p  0.015), whereas multiple zone
metastases only tended toward significance as an adverse
prognostic factor (p  0.054).
Survival Rate According to Prognostic N2
Factors
N2 patients were categorized according to whether they
had significant prognostic factors determined from multivar-
iate analyses, including superior mediastinal lymph nodes
metastases, #11i metastases, or multiple mediastinal meta-
static zones.
The 5-year survival rate was 50.8% in patients without
superior mediastinal lymph nodes metastases, whereas it was
6.4% in patients with superior mediastinal lymph node me-
tastases (p  0.005, Figure 6). The 5-year survival rate was
23.6% in patients without #11i lymph node metastases,
whereas there were no long-term survivors (dead within 3
years) in patients with #11i lymph node metastases (p 
0.008, Figure 7). Furthermore, the 3-year and 5-year survival
rates were 58.2% and 36.4% in patients with single-zone
mediastinal lymph node metastases, whereas they were
29.6% and 0% in patients with multiple-zone mediastinal
lymph node metastases (p  0.01), respectively. Neverthe-
less, by multivariate analysis, superior mediastinal lymph
FIGURE 6. Postoperative survival according to superior me-
diastinal nodal involvement.
TABLE 3. Prognostic Factors for Patients with N2:
Multivariate Analysis
Variables
Odds
Ratio 95% CI p
Model 1
Diameter 1.04 0.99–1.08 0.054
cN
cN1–2/cN0 1.87 0.71–4.95 0.21
Status of lymph node metastases
Superior mediastinal zone 5.08 1.20–21.8 0.03
Multiple zones 1.42 0.51–3.96 0.50
Operative procedure
Pneumonectomy 1.13 0.30–4.34 0.88
Model 2
Diameter 1.03 0.99–1.06 0.17
cN
cN1–2/cN0 1.38 0.54–3.52 0.51
Status of lymph node metastases
#11i 4.80 1.34–17.0 0.015
Multiple zones 2.80 0.98–7.96 0.054
Operative procedure
Pneumonectomy 2.32 0.62–10.0 0.20
#11i, lymph nodes between the right middle and lower lobe bronchi.
TABLE 2. Prognostic Factors for Patients with N2:
Univariate Analysis
Variables Cases
5-yr
Survival (%) p
Gender
Male/female 14/17 17.8/22.0 0.95
Age
70 yr/70 yr or older 22/9 21.7/16.0 0.37
Diameter (14–65 mm, mean: 35 mm)
35 mm/35 mm or larger 16/15 36.5/6.8 0.02
cN
cN1–2/cN0 15/16 8.0/33.7 0.042
cN0–1/cN2 23/8 23.3/12.5 0.24
Adenocarcinoma/others 26/5 25.2/0 0.1
Well differentiated/others 6/25 16.7/21.5 0.81
Pleural involvement yes/no 15/16 21.8/17.3 0.57
Status of lymph node metastases
Superior mediastinal zone yes/no 22/9 6.4/50.8 0.005
Inferior mediastinal zone yes/no 25/6 21.4/16.7 0.61
#12m yes/no 13/18 24.7/18.3 0.92
#11s yes/no 8/23 14.3/21.9 0.14
#11i yes/no 5/26 0/23.6 0.02
Both superior and inferior zones
Multiple zones/single zone 16/15 0/36.4 0.01
Operative procedure
Pneumonectomy vs. others 7/24 0/25.8 0.009
Lobectomy vs. bilobectomy 16/8 23.6/29.2 0.61
Period
Before 1995 vs. from and after 1995 15/16 13.3/28.4 0.28
#12m, lymph nodes adjacent to middle lobe bronchus; #11s, lymph nodes between
the upper lobe bronchus and bronchus intermedius; #11i, lymph nodes between the right
middle and lower lobe bronchi.
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node metastases were revealed to be a stronger prognostic
factor than multiple metastatic zones (Figure 8).
DISCUSSION
There have been many reports on the prognostic
impact of metastasis to specific mediastinal zones, espe-
cially lung cancer in the upper or lower lobes. For patients
with lung cancer with tumor originating in the upper lobe
or division, the frequency of subcarinal lymph node me-
tastases has been reported to range from 3 to 5%, with the
5-year survival rates ranging from 9 to 18%.8–10 The
frequency of superior mediastinal lymph node metastases
has been reported to range from 4 to 5%, with 5-year
survival rates ranging from 0 to 19%.10,11 This low-fre-
quency mediastinal lymph node involvement was highly
associated with multilevel N2, and therefore, the outcomes
were poor.10,12,13 In this study, the frequency of metastases
was similar for the subcarinal and superior mediastinal
zones, and the incidences in N2 patients were 80.6% and
71.0%, respectively. Thus, both superior and inferior me-
diastinal zones were found to be major metastatic sites,
and these results are compatible with previous reports.14
We have revealed that metastases to the superior me-
diastinal lymph nodes are an important independent prognos-
tic factor in patients with N2 middle lobe cancer. This is
similar to what is seen in lower lobe cancer. Nevertheless, the
incidence of skip metastasis to the superior mediastinum is
very different between cancer in the middle lobe and in the
lower lobe. The incidence in this study was 20% for N2 and
has been reported to range from 3 to 4.5% in N2 right lower
lobe cancer.10–12 Furthermore, there was a significant differ-
ence in the 5-year survival rates for superior mediastinal
involvement and inferior mediastinal involvement (6.5% and
50.8%, respectively), even for single-zone N2. When superior
mediastinal lymph nodes were involved, the prognosis was
almost the same as for multilevel N2 patients with middle
lobe cancer.
The most frequent metastatic hilar lymph node was
#12m, and most #11s and #11i metastases were found in
N2 patients. In other words, metastases found in #11s or
#11i indicate N2 disease (#11s: 8/9 and #11i: 5/5). Sur-
prisingly, interlobar (lower lobe: #11i) lymph node in-
volvement was an important adverse prognostic factor,
even in N2 patients. This may be explained by the fact that
there was an association between #11i metastases and
superior mediastinal nodal involvement. Metastasis in #11i
may be understood to be a result of mediastinal nodal
involvement. That is, #11i metastasis is retrograde because
of disturbed antegrade lymph drainage to the superior
mediastinum from mediastinal metastases. Unfortunately,
we could not find any previous reports regarding this
correlation between #11i and superior mediastinal node
involvement. Further investigation is needed to prove the
hypothesis that #11i metastases result from superior me-
diastinal lymph node metastases.
In conclusion, superior mediastinal lymph node metas-
tases and #11i metastases were significant adverse prognostic
factors in patients with middle lobe lung cancer, and they
were associated with each other. Furthermore, in patients
with middle lobe lung cancer, #11i metastases may result
from mediastinal metastases, and the impact on prognosis
must be different from that of patients with cancer in other
lobes.
Limitations of this study include its retrospective na-
ture, including cases from the 1980s, a small sample number,
and that routine adjuvant chemotherapy for N2 patients was
started in 2006. Therefore, in this study, it was difficult to
evaluate the effects on prognosis with respect to adjuvant
chemotherapy.
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